NanoViricidesNNVC
NNVC
About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Employees: 7
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,150% more call options, than puts
Call options by funds: $75K | Put options by funds: $6K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
13% more funds holding
Funds holding: 32 [Q3] → 36 (+4) [Q4]
4% more capital invested
Capital invested by funds: $2.01M [Q3] → $2.09M (+$74.4K) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.19% less ownership
Funds ownership: 11.35% [Q3] → 10.16% (-1.19%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NNVC.
Financial journalist opinion
Based on 4 articles about NNVC published over the past 30 days
Positive
Proactive Investors
5 days ago
NanoViricides evaluating antiviral drug NV-387 for measles treatment
NanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved drug treatment. “A drug for measles is at present a completely missing link in the response to measles virus outbreak,” said Anil Diwan, executive chairman of NanoViricides.
Neutral
Accesswire
5 days ago
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has begun evaluation of its clinical drug NV-387 for the treatment of the Measles virus.
Positive
Proactive Investors
1 week ago
NanoViricides unaffected by US tariff turmoil, says CFO
NanoViricides (NYSE-A:NNVC) chief financial officer Meeta Vyas talked with Proactive about the company's progress developing broad-spectrum antiviral therapeutics and how its technology remains unaffected by global market turmoil. Vyas explained that NanoViricides, based in Shelton, Connecticut, conducts all its research and development in-house, making it immune to international tariff changes.
Positive
Proactive Investors
3 weeks ago
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the agency said last week. The program will prioritize novel treatments and improved diagnostics for poultry, along with vaccine development.
Positive
Proactive Investors
1 month ago
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline
NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending cuts. In a statement, the clinical-stage biotech firm highlighted to shareholders that it develops antiviral treatments, not vaccines, and sees growing demand for broad-spectrum antiviral drugs under the policy direction of US Health and Human Services Secretary Robert Kennedy.
Neutral
Accesswire
1 month ago
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its business is not affected by the tariff policies of the US government or corresponding retaliatory policies of other governments, nor is it affected by the spending cuts being implemented by the current White House administration. Therefore, the Company believes that smart financial strategists would view the longer term strong prospects of the Company (explained below) as supporting the case of NNVC as an effective hedge against the current general stock market turmoil.
Positive
Proactive Investors
1 month ago
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak
NanoViricides (NYSE-A:NNVC) believes its broad-spectrum antiviral NV-387 could provide a crucial weapon piece in the fight against the ongoing measles outbreak in the US. The company responded to a recent opinion piece by Health and Human Services Secretary Robert F.
Neutral
Accesswire
1 month ago
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us".
Positive
Proactive Investors
1 month ago
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.
Neutral
Accesswire
1 month ago
NanoViricides, Inc. Has Filed its Quarterly Report
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending December 31, 2024 with the Securities and Exchange Commission (SEC) on Friday, February 14, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057825000140/nnvc-20241231x10q.htm).
Charts implemented using Lightweight Charts™